Rhythm Pharmaceuticals, Inc. (RYTM) | Investment Case

1. Company Snapshot

1.a. Company Description

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity.The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders.

Rhythm Pharmaceuticals, Inc.has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome.The company was formerly known as Rhythm Metabolic, Inc.

and changed its name to Rhythm Pharmaceuticals, Inc.in October 2015.Rhythm Pharmaceuticals, Inc.

was founded in 2008 and is headquartered in Boston, Massachusetts.

Show Full description

1.b. Last Insights on RYTM

Breaking News: Rhythm Pharmaceuticals reported positive Phase 3 data for its obesity treatment, showing an 18.8% BMI drop in rare obesity patients. The company's shares rose following the announcement. A FDA decision on the obesity drug is expected by March 20. Analysts at Cantor Fitzgerald upgraded the stock to overweight from neutral, citing the promising data. RBC Capital Markets also upgraded the stock to outperform from sector perform, citing the significant BMI reduction.

1.c. Company Highlights

2008 - Rhythm Pharmaceuticals, Inc. was founded by a team of entrepreneurs and scientists with expertise in genetics, genomics, and biotechnology.

2010 - The company raised $40 million in Series A financing to support the development of its genetic obesity therapies.

2014 - Rhythm Pharmaceuticals, Inc. initiated its Phase 2 clinical trial of setmelanotide, a melanocortin-4 receptor (MC4R) agonist, in patients with rare genetic disorders of obesity.

2017 - The company raised $80 million in Series B financing to advance its pipeline of genetic obesity therapies.

2019 - Rhythm Pharmaceuticals, Inc. reported positive Phase 2 data for setmelanotide in patients with pro-opiomelanocortin (POMC) deficiency obesity.

2020 - The company submitted a New Drug Application (NDA) to the FDA for setmelanotide for the treatment of POMC deficiency obesity.

2022 - Rhythm Pharmaceuticals, Inc. received FDA approval for IMCIVREE (setmelanotide) for the treatment of obesity due to POMC, PCSK1, or LEPR deficiency.

Last Price	89.56
Change Percentage	-5.67%
Open	92.75
Previous Close	94.94
Market Cap ( Millions)	5977
Volume	1523998
Year High	122.2
Year Low	45.91
M A 50	104.12
M A 200	94.17

FCF Yield	-1.95%
Dividend Yield	0.00%
ROE	-179.05%
Debt / Equity	177.23%
Net Debt / EBIDTA	-110.37%
Price To Book	43.07
Price Earnings Ratio	-30.47
Price To FCF	-51.25
Price To sales	31.5
EV / EBITDA	-35.43

2. Rhythm Pharmaceuticals' Strong Q4 2025 Results: A Year of Growth and Progress

Rhythm Pharmaceuticals reported a robust Q4 2025, with IMCIVREE revenues reaching $57.3 million, a 12% quarter-over-quarter increase and a 37% year-over-year increase. The company's net product revenues in Q4 2025 increased by $15.4 million, or 37%, over Q4 2024. Gross to net for US sales was approximately 84.6%, while cost of goods sold was 8.5% of product revenue. The actual EPS came out at '-0.73025', beating estimates at '-0.79'. Research and development expenses were $42 million for Q4, compared to $41.2 million in the same quarter last year, while SG&A expenses were $57.5 million for Q4 2025, up from $38.1 million in Q4 last year.

Publication Date: Mar -02

                                    📋 Highlights
                                    Q4 2025 Revenue Growth::
                                                IMCIVREE sales reached $57.3M (+12% QoQ) and $194.8M for the full year, with 37% YoY growth in the US ($39M) and international markets ($18.3M).
Bivamelagon Phase 2 Success::
                                                Achieved 14.3% mean BMI reduction in HO patients at 40 weeks, advancing to Phase 3 by late 2026.
IMCIVREE Expansion::
                                                Available in 25+ countries, with EU HO approval expected by late 2026 (CHMP opinion Q2 2026) and potential launch in Japan within 12 months.
Financial Strength::
                                                Ended 2025 with $389M in cash, funding operations for 24 months, and plans $385–415M non-GAAP 2026 expenses.
Inventory and Cost Efficiency::
                                                Gross-to-net for US sales at 84.6%, COGS at 8.5% of revenue, and $1.3M inventory swing due to US vial distribution.

                                

Financial Position and Guidance

The company ended 2025 with approximately $389 million in cash equivalents and short-term investments, expected to fund planned operations for at least 24 months. For 2026, the company anticipates non-GAAP operating expenses of $385 million-$415 million, including non-GAAP R&D expenses of $197 million-$213 million and non-GAAP SG&A expenses of $188 million-$202 million. Analysts estimate next year's revenue growth at 84.6%.

Clinical Progress and Pipeline Updates

The company's phase 2 study of bivamelagon for hypothalamic obesity (HO) showed positive results, with patients achieving a mean BMI reduction of up to 14.3% at 40 weeks. The FDA confirmed that bivamelagon is ready to move to phase 3, which is expected to start by year-end 2026. The company is also preparing for the potential launch of IMCIVREE for acquired HO, pending regulatory approval and the March 20th PDUFA goal date.

Valuation and Growth Prospects

With a P/S Ratio of 32.61, the market is pricing in significant growth expectations for Rhythm Pharmaceuticals. The company's EV/EBITDA ratio stands at -35.25, indicating that the market is factoring in substantial future growth. As the company continues to make progress in its clinical programs and expands its market presence, investors will be watching closely to see if the company can meet these expectations.

Future Developments and Opportunities

The company is exploring other areas of MC4R development, including genetics, with the DAYBREAK study, and potentially other approaches to obesity. The company plans to submit separate sNDAs for each of the four genetic indications in the EMANATE study and is considering a phase 3 trial for Prader-Willi syndrome. With a strong financial position and a robust pipeline, Rhythm Pharmaceuticals is well-positioned for future growth and development.

3. NewsRoom

Rhythm Pharmaceuticals Discloses 18.8% BMI Drop In Rare Obesity Patients

Mar -02

Source: feeds.benzinga.com

Rhythm Pharmaceuticals Announces Additional Positive Data from Phase 3 TRANSCEND trial of Setmelanotide in Patients with Acquired Hypothalamic Obesity

Mar -01

Source: globenewswire.com

Rhythm Pharmaceuticals, Inc. (RYTM) Q4 2025 Earnings Call Transcript

Feb -26

Source: seekingalpha.com

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q4 Loss, Beats Revenue Estimates

Feb -26

Source: zacks.com

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb -26

Source: globenewswire.com

Hillsdale Investment Management Inc. Takes $4.30 Million Position in Rhythm Pharmaceuticals, Inc. $RYTM

Feb -23

Source: defenseworld.net

Rhythm Pharmaceuticals Is Well-Positioned, Analyst Says Could Capture Big Share Of Rare Obesity Market

Feb -19

Source: benzinga.com

Here Are Thursday’s Top Wall Street Analyst Research Calls: Analog Devices, Chewy, Credo Technology, eBay, Fiverr, Shopify, Verizon, and More

Feb -19

Source: 247wallst.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.90%)

6. Segments

Therapeutics

Expected Growth: 25.9%

Growing prevalence of rare genetic disorders, increasing awareness of peptide therapeutics, and Rhythm's lead candidate setmelanotide's potential to address unmet needs in POMC, PCSK1, and LEPR deficiency drive growth in this segment.

7. Detailed Products

Setmelanotide

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist, a novel, first-in-class therapy for the treatment of obesity and rare genetic disorders of obesity.

IMCIVREE

IMCIVREE is a melanocortin-4 receptor (MC4R) agonist, a novel, first-in-class therapy for the treatment of obesity and rare genetic disorders of obesity.

8. Rhythm Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Rhythm Pharmaceuticals, Inc. operates in the biotechnology industry, which is characterized by high research and development costs. This makes it difficult for substitutes to emerge, reducing the threat of substitutes.

Bargaining Power Of Customers

Rhythm Pharmaceuticals, Inc. primarily sells its products to healthcare providers and patients, who have limited bargaining power due to the specialized nature of the company's products.

Bargaining Power Of Suppliers

Rhythm Pharmaceuticals, Inc. relies on a limited number of suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers mitigate this risk.

Threat Of New Entrants

The biotechnology industry has high barriers to entry, including significant research and development costs, regulatory hurdles, and the need for specialized expertise. This makes it difficult for new entrants to enter the market.

Intensity Of Rivalry

The biotechnology industry is highly competitive, with many established players and new entrants vying for market share. Rhythm Pharmaceuticals, Inc. faces intense competition from companies with similar products and pipelines.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	0.74%
Debt Cost	14.29%
Equity Weight	99.26%
Equity Cost	14.29%
WACC	14.29%
Leverage	0.74%

11. Quality Control: Rhythm Pharmaceuticals, Inc. passed 2 out of 9 key points

Strong Liquidity

Low Deb

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

PTC Therapeutics

A-Score: 5.8/10

Value: 7.8

Growth: 5.6

Quality: 8.4

Yield: 0.0

Momentum: 9.5

Volatility: 3.3

1-Year Total Return ->

BioMarin Pharmaceutical

A-Score: 4.8/10

Value: 5.0

Growth: 8.4

Quality: 8.0

Yield: 0.0

Momentum: 1.5

Volatility: 6.0

1-Year Total Return ->

Rhythm Pharma

A-Score: 4.6/10

Value: 6.0

Growth: 5.1

Quality: 4.1

Yield: 0.0

Momentum: 9.5

Volatility: 2.7

1-Year Total Return ->

Cytokinetics

A-Score: 4.0/10

Value: 8.0

Growth: 0.4

Quality: 4.9

Yield: 0.0

Momentum: 9.0

Volatility: 1.7

1-Year Total Return ->

Celldex Therapeutics

A-Score: 3.8/10

Value: 6.7

Growth: 3.0

Quality: 5.1

Yield: 0.0

Momentum: 5.0

Volatility: 3.0

1-Year Total Return ->

Amicus Therapeutics

A-Score: 3.6/10

Value: 0.4

Growth: 7.4

Quality: 4.6

Yield: 0.0

Momentum: 5.5

Volatility: 3.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

55.17%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

14.29%

Rhythm Pharmaceuticals, Inc. - US76243J1051

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on RYTM

1.c. Company Highlights

Strong Momentum

Average Growth

Fairly Valued

Revenues Miss

Average Quality

Earnings Beats

Revenues Beats

Stable Momentum

Earnings Miss

Average Yield

Lower Growth

2. Rhythm Pharmaceuticals' Strong Q4 2025 Results: A Year of Growth and Progress

Financial Position and Guidance

Clinical Progress and Pipeline Updates

Valuation and Growth Prospects

Future Developments and Opportunities

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (25.90%)

6. Segments

Therapeutics

Expected Growth: 25.9%

7. Detailed Products

Setmelanotide

IMCIVREE

8. Rhythm Pharmaceuticals, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Rhythm Pharmaceuticals, Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

89.56$

Current Price

89.56$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA